

IntelGenx Technologies Corp.  
Form 8-K  
July 13, 2016

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**Current Report**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**July 13, 2016**  
Date of Report (Date of Earliest Event Reported)

**INTELGENX TECHNOLOGIES CORP.**  
(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-31187**  
(Commission File  
Number)

**870638336**  
(IRS Employer Identification  
No.)

6420 Abrams, Ville St- Laurent, Quebec, Canada  
(Address of principal executive offices)

**H4S 1Y2**  
(Zip Code)

Registrant's telephone number, including area code: **(514) 331-7440**

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))  
 Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 8.01 Other Events - News Release**

## **IntelGenx to Initiate Phase 1 Trial of Montelukast**

Exhibit Description

99.1 Press Release

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **INTELGENX TECHNOLOGIES CORP.**

Dated: July 13, 2016 By: */s/ Horst G. Zerbe*

-----  
Horst G. Zerbe  
President and Chief Executive Officer

---